Literature DB >> 25185243

Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

D A Eichenauer1, A Engert1, M André2, M Federico3, T Illidge4, M Hutchings5, M Ladetto6.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25185243     DOI： 10.1093/annonc/mdu181

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  42 in total

1.  Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group.

Authors:  D A Eichenauer; H Goergen; A Plütschow; D Wongso; K Behringer; S Kreissl; I Thielen; T Halbsguth; P J Bröckelmann; M Fuchs; B Böll; B von Tresckow; P Borchmann; A Engert
Journal:  Leukemia       Date:  2015-11-20       Impact factor: 11.528

2.  Baseline and ongoing PET-derived factors predict detrimental effect or potential utility of 18F-FDG PET/CT (FDG-PET/CT) performed for surveillance in asymptomatic lymphoma patients in first remission.

Authors:  Silvia Morbelli; Selene Capitanio; Fabrizio De Carli; Francesca Bongioanni; Enrico De Astis; Maurizio Miglino; Maria Teresa Verardi; Ambra Buschiazzo; Francesco Fiz; Cecilia Marini; Elena Pomposelli; Gianmario Sambuceti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-19       Impact factor: 9.236

Review 3.  FDG PET/CT imaging as a biomarker in lymphoma.

Authors:  Michel Meignan; Emmanuel Itti; Andrea Gallamini; Anas Younes
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-09       Impact factor: 9.236

4.  Advanced Hodgkin's lymphoma: End-of-treatment FDG-PET should be maintained.

Authors:  Elif Hindié; Charles Mesguich; Krimo Bouabdallah; Noël Milpied
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08       Impact factor: 9.236

5.  Major haemorrhage requiring transarterial embolisation following open biopsy of an unusual neck mass.

Authors:  M Walsh; M Supriya; N Railton
Journal:  Ann R Coll Surg Engl       Date:  2017-07       Impact factor: 1.891

6.  Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study.

Authors:  Julien Lazarovici; Peggy Dartigues; Pauline Brice; Lucie Obéric; Isabelle Gaillard; Mathilde Hunault-Berger; Florence Broussais-Guillaumot; Emmanuel Gyan; Serge Bologna; Emmanuelle Nicolas-Virelizier; Mohamed Touati; Olivier Casasnovas; Richard Delarue; Frédérique Orsini-Piocelle; Aspasia Stamatoullas; Jean Gabarre; Luc-Matthieu Fornecker; Thomas Gastinne; Fréderic Peyrade; Virginie Roland; Emmanuel Bachy; Marc André; Nicolas Mounier; Christophe Fermé
Journal:  Haematologica       Date:  2015-10-01       Impact factor: 9.941

7.  Interim FDG-PET in lymphoma, a questionable practice in hematology.

Authors:  Hugo J A Adams; Thomas C Kwee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-07-31       Impact factor: 9.236

8.  Imaging children suffering from lymphoma: an evaluation of different 18F-FDG PET/MRI protocols compared to whole-body DW-MRI.

Authors:  Julian Kirchner; Cornelius Deuschl; Bernd Schweiger; Ken Herrmann; Michael Forsting; Christian Buchbender; Gerald Antoch; Lale Umutlu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-22       Impact factor: 9.236

9.  Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma.

Authors:  Scott F Huntington; Gottfried von Keudell; Amy J Davidoff; Cary P Gross; Sapna A Prasad
Journal:  J Clin Oncol       Date:  2018-10-04       Impact factor: 44.544

Review 10.  FDG-PET imaging in hematological malignancies.

Authors:  L Valls; C Badve; S Avril; K Herrmann; P Faulhaber; J O'Donnell; N Avril
Journal:  Blood Rev       Date:  2016-04-16       Impact factor: 8.250
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.